A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas.

@article{Jundt2005ARD,
  title={A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein \{beta\} and NF-\{kappa\}B activity in Hodgkin and anaplastic large cell lymphomas.},
  author={Franziska Jundt and Nina Raetzel and Christine M{\"u}ller and Cornelis F Calkhoven and Katharina Kley and Stephan Mathas and Andreas Lietz and Achim Leutz and Bernd Doerken},
  journal={Blood},
  year={2005},
  volume={106 5},
  pages={1801-7}
}
The immunosuppressive macrolide rapamycin and its derivative everolimus (SDZ RAD, RAD) inhibit the mammalian target of rapamycin (mTOR) signaling pathway. In this study, we provide evidence that RAD has profound antiproliferative activity in vitro and in NOD/SCID mice in vivo against Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) cells. Moreover, we identified 2 molecular mechanisms that showed how RAD exerts antiproliferative effects in HL and ALCL cells. RAD down-regulated… CONTINUE READING
62 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 62 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Similar Papers

Loading similar papers…